Dr. Nicolas Loebel from Ondine Biomedical joins Natalie Stoberman from the Proactive studio to share updates about two main studies.
Dr. Loebel says phase-2 clinical trial of Ondine Biomedical's nasal photodisinfection technology has met its primary and secondary endpoint targets. In addition, Dr. Loebel explains the company has received funding of up to US$735,000 to develop a novel photodisinfection prototype for use in Canada's meat packing industry.